News
31 March 2020

EIB finances AM-Pharma's development of acute kidney injury treatment

In:
Infrastructure
Region:
Europe

The EIB and Utrecht-based AM-Pharma have signed a €24 million financing agreement. The funds will be used to accelerate the development of the clinical stage biopharmaceutical company’s recombinant alkaline phosphatase enzyme, which is used to treat acute kidney injury (AKI). The...

Exclusive subscriber content…

If you are a TXF subscriber, please login to continue reading

Login

Not yet a subscriber? Join us today to continue accessing content without any restrictions

View our subscription options

Or to request access to TXF Intelligence contact us

Request Access

You might also like


Perspective
03 September 2026

Taean: A Korean offshore wind test case for ECAs

The embryonic Korean offshore wind market is a long way off project finance adolescence. A viable ECA-backed template for big-ticket projects is set to emerge next year – but...

Perspective
03 September 2026

Serica and Adura: A modest comeback for North Sea RBLs

Serica Energy’s oversubscribed $750 million refinancing and Adura’s $3 billion RBL show that bank liquidity is returning to the UK’s North Sea. But it is returning on terms...